Efavirenz-associated breast hypertrophy in HIV-infection patients.
Mercié
P
P
Clinique de Médecine Interne et Maladies Infectieuses, H pital Haut-Léveque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France.
Viallard
J F
JF
Thiébaut
R
R
Faure
I
I
Rispal
P
P
Leng
B
B
Pellegrin
J L
JL
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D001941:Breast Diseases / Q000139:chemically induced*; D003521:Cyclopropanes; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000009:adverse effects* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz